dm+d
Unassigned
New Medicines
Severe haemophilia A and B, with or without inhibitors.
Information
New molecular entity
Pfizer
Pfizer
Development and Regulatory status
Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes
Category
Human monoclonal immunoglobulin G subclass 1 (IgG1) that targets the Kunitz 2 domain of tissue factor pathway inhibitor (TFPI)
Haemophilia results from mutations in the Factor VIII gene leading to blood clotting delay. Haemophilia A affects 1:4,000 to 1:5,000 live male births worldwide and is five times as common as haemophilia B (factor IX deficiency)[2].
Severe haemophilia A and B, with or without inhibitors.
Subcutaneous